Category: Alzheimer’s Disease

SARM1 Inhibitors: A Novel Approach Against Neurodegenerative Disorders

Presently, several industry and non-industry stakeholders are evaluating SARM1 inhibitors as potential therapeutic agents for the treatment of neurological disorders across various preclinical studies and early stages of clinical development, worldwide. Given the encouraging research outcomes, the players in this domain have received more than USD 10 million in grants, since 2014, from the various

Alzheimer’s Disease and Its Evolving Market

Alzheimer’s disease is a progressive neurological disorder characterized by the death of brain cells, eventually leading to memory loss, cognitive dysfunction and dementia. Accounting for 60-70% cases of dementia, Alzheimer’s disease is known to be the sixth leading cause of death in the US.   Presently, more than 6 million Americans of all ages are living

Alzheimer’s Disease Market: Pipeline Review, Developer Landscape and Competitive Insights

It was estimated that, in 2018, nearly 5.7 million Americans (considering all age groups) were living with Alzheimer’s disease. During the same year, Alzheimer’s Disease Market and other dementias were projected to be responsible for a healthcare burden amounting to USD 277 billion, in the US. Despite extensive research aimed at comprehending the etiopathogenesis of